Journal of Medical Ethics, Volumen 28, Issue 1, 2018, Pages 24-27
Identifier
dc.identifier.issn
03066800
Identifier
dc.identifier.other
10.1136/jme.28.1.24
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/163491
Abstract
dc.description.abstract
Clinical and research practices designed by developed countries are often implemented in host nations of the Third World. In recent years, a number of papers have presented a diversity of arguments to justify these practices which include the defence of research with placebos even though best proven treatments exist; the distribution of drugs unapproved in their country of origin; witholding of existing therapy in order to observe the natural course of infection and disease; redefinition of equipoise to a more bland version, and denial of post-trial benefits to research subjects. These practices have all been prohibited in developed, sponsoring countries, even though they invariably have pockets of poverty where conditions comparable to the Third World prevail. Furthermore, the latest update of the Declaration of Helsinki clearly decries double ethical standards in research protocols. Under these circumstances, it does not seem appropriate that First World scholars should propose and d